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Abstract: Lentiviruses induce a wide variety of pathologies in different animal species. A 
common  feature  of  the  replicative  cycle  of  these  viruses  is  their  ability  to  target  
non-dividing cells, a property that constitutes an extremely attractive asset in gene therapy. 
In this review, we shall describe the main basic aspects of the virology of lentiviruses that 
were exploited to obtain efficient gene transfer vectors. In addition, we shall discuss some 
of the hurdles that oppose the efficient genetic modification mediated by lentiviral vectors 
and the strategies that are being developed to circumvent them. 
Keywords: lentivirus; lentiviral vector; gene therapy; HIV; SIV; EIAV; FIV 
 
1. Introduction: On Lentiviruses and Their Natural Cellular Targets 
1.1. Virus Replication and Pathology 
Lentiviruses owe their lenti appellative (slow in latin) to the long period of time elapsing between 
the initial infection and the onset of the disease, that can protract over a period of months or even 
years. Viruses belonging to the Lentivirus genus are present in primates, ungulates (horse, cattle, sheep 
and goat) and felids (cat) (for reviews see [1,2]). Primates are the natural host for several lineages of 
closely related simian and human immunodeficiency viruses (SIV and HIV, respectively) that are the 
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etiologic agents of the acquired immunodeficiency syndrome (AIDS) [3–5]. In monkeys, SIVs are 
divided in five lineages according to their host species: sooty mangabey, SM; african green monkey, 
AGM; chimpanzee, CPZ; mandrill, MND; syke, SYK. Transmission of these simian viruses to humans 
gave raise to two genetically distinct viruses: HIV-1, closely related to SIVCPZ and HIV-2, closely 
related  to  SIVSM.  Both  HIV-1  and  HIV-2  cause  AIDS.  However,  while  HIV-1  induces  a  rapid 
syndrome in the absence of anti viral treatment and is responsible for AIDS worldwide, HIV-2 infected 
individuals develop AIDS with substantially slower kinetics and its distribution is essentially restricted 
to West Africa [6–8]. Interestingly, SIVs are capable of developing a peaceful relationship with their 
host,  since  SIV  infection  is  non-pathogenic  in  the  natural  host.  However,  the  infection  becomes 
pathogenic  when  transmitted  to  a  different  species,  as  is  the  case  in  experimental  infections  of 
monkeys, or as has been the case in humans (a number of recent reviews illustrate these aspects in 
detail, [9–13]. Among ungulates, sheep is the natural host for the Visna/maedi virus (VMV), goats for 
the caprine arthritis-encephalitis virus (CAEV), cattle for the bovine immunodeficiency virus (BIV), 
and horses for the equine infectious anemia virus (EIAV) [2]. Finally, domestic and wild cats are 
infected with the feline immunodeficiency virus (FIV) that induces an AIDS-like syndrome [14].  
Historically, the first description of a lentiviral induced disease came from the observation of a 
slowly progressive disorder in the sheep flocks present in Iceland during the 1950s. This disease was a 
severe form of pneumo-encephalopathy that gave its name at its causal virus (paralysis and wasting, 
i.e.,  visna  and  labored  breathing,  known  as  maedi,  in  Icelandic)  [15,16].  Despite  the  variety  of 
pathologies they induce, lentiviral infections share several common features. De novo infection is 
characterized by an acute phase of viral replication that is transitory and that rapidly progresses into a 
chronic  period.  This  long  chronic  phase  in  which  viral  replication  is  substantially  diminished 
characterizes the pathogenesis induced by most lentiviruses, from the severe immunodeficiency caused 
by primate and feline immunodeficiency viruses, to the synovitis in CAEV-infected goats or to the 
severe  pneumo-encephalopathy  observed  in  VMV-infected  sheep.  During  this  period,  lentiviruses 
continue to replicate and gradually subvert, as is the case of primate immunodeficiency viruses, host 
defenses. After this chronic phase the disease becomes manifest. Not all lentiviruses are associated to a 
disease,  as  is  the  case  for  BIV  which  causes  only  mild  symptoms  in  infected  cattle  (namely 
lymphocytosis), although more pathogenic strains of BIV have recently been isolated [17,18]. Besides 
a certain number of exceptions to this general description do exist. For example, lentiviral infection 
can  rapidly  lead  to  the  onset  of  the  disease,  as  observed  in  HIV-1-infected  newborns,  or  in  
CAEV-infected kid goats. In the case of EIAV infection, the chronic phase is not established after the 
initial infection, but rather after the disease. Indeed, infected animals develop anemia quite rapidly 
after infection and subsequently enter a relatively asymptomatic chronic state. This state is interrupted 
by cycles of peak viremia and disease that protracts during the entire life span of the animal [2].  
1.2. Myeloid Cells as a Preferential Target for Lentiviruses 
Myeloid cells include a large panel of cell types with specialized functions. Blood monocytes are 
precursors that leave the circulation in response to tissue damage or infection and enter tissues where 
they differentiate into macrophages or dendritic cells (DCs). These are professional antigen presenting 
cells (APCs) that play a central role in the orchestration of host immune responses [19–22]. Following Viruses 2011, 3                                       
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a  similar  migratory  pattern,  monocytes  are  also  able  to  cross  the  blood-brain  barrier  before 
differentiating into microglia cells in the central nervous system. Overall, these cell types are not 
homogeneous, but are constituted by highly heterogeneous cell subtypes performing specific functions. 
For  example,  at  least  two  sets  of  monocytes  co-exist  in  the  blood:  CD16
−CD14
+  cells,  the  most 
abundant monocyte population in the blood and CD16
+CD14
+ cells, a minor monocyte population with 
a more activated phenotype (about 1 to 5% of circulating monocytes) [23–26]. The presence of distinct 
cell subtypes is common not only to monocytes, but also macrophages and DCs. To add to the extreme 
complexity of cells of the myeloid lineage, these cells have the ability to polarize in response to the 
surrounding environment (for example into M1 or M2 macrophages) and to exert distinct functions 
[22]. A more extended introduction on the plasticity of myeloid cells would fall beyond the scope of 
this review and the reader is referred to other reviews that have covered these aspects [22,26,27].  
Despite the fact that lentiviruses infect different cell types, all seem to share an exquisite ability to 
target cells of the myeloid lineage in vivo (as for VMV, CAEV, HIV, SIV and FIV) [28–35]. In the 
case of EIAV the tropism for monocyte-macrophages is extreme, because these cells seem to be the 
only ones infected (including Kupffer cells that are macrophage-like cells in the liver) [36]. In the case 
of HIV, the virus is primarily transmitted as a CCR5-tropic virus, a co-receptor present on cells of the 
myeloid  lineage in  addition to gut-associated lymphocytes [37–40].  To strengthen this  point, it is 
interesting to note that lentiviral infection causes a variety of neurological disorders that result from 
viral replication in the central nervous system (CNS) [41–43]. Given that monocytes are the sole cell 
type that under normal conditions is able to traverse the blood-brain barrier, it is clear that the virus 
must use these cells to gain access to this privileged site. 
The relationship established between myeloid cells and lentiviruses is multifaceted. For example, 
EIAV  and  VMV  integrate  as  proviruses  into  circulating monocytes, however  their  genome  is  not 
expressed  until  these  cells  differentiate  into  macrophages,  a  phenomenon  called  post-integration 
silencing [44–48]. Instead, HIV-1 delays integration for days after entry in non-stimulated monocytes, 
thus achieving pre-integrative silencing [49–53]. Albeit different, these silencing strategies may allow 
the virus to remain under cover within monocytes thus minimizing their exposure to the immune 
system. Afterward when monocytes enter the tissues and become activated, the virus is able to exit this 
covert  phase  and  resumes  its  replication  cycle  [44,52,54].  This  mode  of  action  offers  a  double 
advantage to the virus: to profit from the migratory behavior of monocytes to reach sites in which viral 
spread can occur, as the lymph nodes or the CNS; to be present within the very cells that ought to 
instruct antiviral responses. The consequence of the latter is the possibility for the virus to modify the 
behavior of these antigen presenting cells and thus to influence antiviral immune responses.  
These considerations are not meant to diminish the importance that the infection of other cell types 
has in the pathogenesis caused by the different lentiviruses, but is meant to suggest that these viruses 
may have evolved certain common features that allow them to target myeloid cells. In light of their 
multiple roles, these cells are of interest for a wide variety of applications that range from anti-cancer 
strategies, to vaccination and antiviral immunity [55,56]. From a virological point of view, these cells 
are non-dividing cells and this implies that the viral genome must traverse an intact nuclear membrane 
to  access  the  cellular  genome.  Among  retroviruses,  lentiviruses  have  evolved  the  most  efficient 
machinery to achieve this goal, a property that is highly valuable in gene therapy.  
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2. Basic Aspects of Virology Applied to Lentivectors 
2.1. An Introduction to the Early Phases of the Viral Life Cycle 
The  viral  life  cycle  can  be  divided  into  two  main  phases:  one  in  which  the  viral  genome  is 
transferred into the host cell and one in which this genome is expressed and viral propagation assured. 
The main interest of viral vectors for gene therapy purposes lays in the first, collectively referred to as 
the  early  steps  of  the  viral  life  cycle.  This  process  can  be  defined  as  gene  transduction  (in  gene 
therapy)  or  single  cycle  infection  (in  virology)  and  both  terms  will  be  used  here.  In  the  case  of 
retroviruses,  the  infection  starts  with  the  engagement  of  a  specific  cellular  receptor  by  the  viral 
envelope and culminates in the integration of the neo-synthesized full length viral DNA into the host 
cell genome. The cellular receptor-viral Env engagement triggers the fusion between the plasma cell 
and  the  particle  membranes  and  results  in  the  release  of  a  viral  nucleoprotein  complex  (VNC) 
composed of the viral genome associated to viral and cellular proteins in the cytoplasm of target cells. 
The exact composition of VNCs has proven particularly difficult to establish due to different reasons. 
These structures are labile and change over time as they accommodate the conversion of the viral 
genome from an RNA to a double stranded DNA molecule. In addition, for reasons that are currently 
unknown, a large proportion of VNCs present during infection is non-functional and this complicates 
the analysis of the composition of truly infectious VNCs. Nonetheless, a number of notions as to their 
composition and trafficking have been gathered and will be discussed below. If this rather general 
description applies to all retroviruses, the infection of non-dividing cells requires the viral genome to 
traverse the nuclear membrane to access the host genome. This step, key for gene therapy purposes in 
non-dividing cells, is termed nuclear import. 
2.2. An Efficient Nuclear Import, the Distinctive Feature of Lentiviruses 
The nuclear membrane  constantly  regulates exchanges between the cytoplasm and the nucleus, 
apart from  a  brief period in  which it is removed  during mitosis. These exchanges  depend on the 
nuclear  pore,  a  multiprotein  structure  that  allows  free  exchanges  of  small  molecules,  but  that 
selectively controls the transport of molecules of a molecular weight superior to 40 kDa [57]. Proteins 
localized  in  the  nucleus  possess  a  nuclear  localization  signal  (NLS)  by  virtue  of  which  they  are 
recognized  by  karyopherins,  or  importins,  that  are  the  cellular  cytoplasm-nucleus  transporters.  In 
humans,  karyopherins  are  divided  in  two  families  comprising  multiple  members  (6  and  20  for 
karyopherins α and β, respectively). The NLS is recognized either directly by karyopherin β or via the 
karyopherin α adaptor that associates to karyopherin β. The cargo-karyopherin complex is transported 
through  the  nuclear  pore  into  the  nucleus  via  interactions  with  several  of  its  constituents,  the 
nucleoporins. The asymmetric distribution of the GTP/GDP bound forms of the Ras-related nuclear 
protein, the Ran GTPase, is responsible for the directionality of this transport toward the nucleus. The 
GTP-bound form of Ran (RanGTP) is primarily found in the nucleus, where it binds to the imported 
complex dissociating the karyopherin from its cargo. The karyopherin-RanGTP complex shuttles back 
into the cytoplasm, where it dissociates upon hydrolysis of GTP to GDP. RanGDP is then transported 
back to the nucleus by a specific transporter, the nuclear transport factor 2 (NTF2), so that the cycle 
can start anew. These movements are possible because of the high and low affinities that Ran displays Viruses 2011, 3                                       
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for karyopherins in its GTP- or GDP-bound state, respectively. The directionality of the transport relies 
also on a Ran gradient that is maintained by the Ran guanine exchange factor (RanGEF, that charges 
Ran with GTP in the nucleus) and by the Ran GTPase activating protein (RanGAP, that mediates the 
hydrolysis of GTP in GDP in the cytoplasm). 
For the purposes of viral infection, the nuclear membrane is an additional obstacle that can be 
bypassed either by taking advantage of its natural removal during cell division, or by traversing the 
nuclear  pores.  Intuitively,  the  latter  is  the  only  possibility  available  in  non-dividing  cells.  The 
relationship  between  retroviruses  and  nuclear  membrane  remains  surrounded  by  a  number  of 
questions.  For  example,  although  simple  retroviruses  are  impaired  in  the  transduction  of  
growth-arrested cells, there is no proof that they truly access the nucleus in that short window of time 
during which the nuclear membrane is absent in dividing cells. Similarly, although lentiviruses must 
traverse the nuclear pore during the infection of non-dividing cells, it remains unclear whether this step 
is optional or obligatory during the infection of dividing cells.  
Aside from these considerations and despite the fact that other retroviruses are able to accomplish 
infection of non-dividing cells [58–61], lentiviruses certainly appear the most efficient ones to carry 
out nuclear import. In light of their exquisite tropism for non-dividing myeloid cells, it is tempting to 
speculate that they have perfected this property through evolution.  
Over the years, a number of studies attempted to identify determinants of nuclear import and, as 
most  of  the  work  has  been  focused  on  HIV-1,  we  shall  use  this  virus  as  a  paradigm  for  other 
lentiviruses.  The  literature  on  the  subject  is  vast,  and  has  often  been  contradictory  due  to  the 
heterogeneity of the experimental systems used and to the relative complexity of nuclear import (for 
reviews, see [57,62–64]). However, a certain consensus is now apparent, as we will discuss below.  
Historically,  potential  factors  that  mediate  nuclear  import  were  sought  among  components  of 
VNCs.  Among  them,  the  search  was  directed  at  nucleophilic  elements  specific  to  lentiviruses.  A 
number of proteins met these criteria, namely Matrix (MA), Integrase (IN) and Vpr. The first two are 
structural components of viral particles and are conserved among retroviruses. However, NLSs seem 
present  uniquely  in  lentiviral  MA  and  IN  proteins.  Instead,  Vpr  is  a  non-structural  viral  protein 
incorporated into particles and  is coded solely by primate lentiviruses.  Despite the fact that these 
proteins localized to the nucleus, their role during nuclear import turned out to be negligible, as most 
defects observed upon their mutagenesis were due to pleiotropic effects, rather than to an effect on 
nuclear import per se (compare the above mentioned reviews with older reviews on the subject, [65–67]. 
Retrospectively, failure to reveal a major role in nuclear import for these proteins was just as possible 
as the contrary would have been. Indeed, even if a protein  is nuclear when expressed outside its 
context, it may not be so when part of a higher order molecular complex (such as the VNC). This may 
be due to different reasons, given that a particular protein may be present in limited amounts in the 
complex  to  drive  it  into  the  nucleus,  or  else  it  may  not  be  exposed  to  physically  associate  to 
components of the nucleo-cytoplasmic transport machinery. Following a similar rationale, early studies 
focused on a particular sequence present almost exclusively in the genome of lentiviruses, named the 
central polypurine tract-central termination sequence (cPPT-CTS) [68]. The cPPT sequence is present 
roughly in the middle of the viral genome and, similar to the polypurine tract present at the 3’ of the 
viral genome, it resists RNaseH-mediated degradation and acts as an internal primer for viral DNA 
synthesis. The CTS is located downstream of the cPPT and is the site at which plus strand viral DNA Viruses 2011, 3                                       
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synthesis  terminates.  Presence  of  the  cPPT-CTS  determines  a  discontinuity  in  the  plus  strand  of 
completed viral DNA that yields a triple helix structure, a DNA flap, that is later resolved in an 
integrated provirus.  Although a central discontinuity region has been evidenced in the genome of 
primate foamy viruses [69] and in yeast retrotransposons [70], it is unclear whether this region yields 
to the formation of a DNA flap and whether it acts similarly to the one present in lentiviruses [71]. In 
lentiviral vectors, presence of the cPPT-CTS exerts a positive effect on viral infectivity on most cells 
[72–74]. Although initial studies conferred a prime role to this structure in nuclear import [74], the first 
generation  of  lentiviral  vectors  was  devoid  of  cPPT-CTS  and  was  still  capable  of  transducing  
non-dividing cells [75]. This and other studies tempered the enthusiasm over the role of the cPPT-CTS 
in  nuclear  import,  implying  that  although  it  could  contribute  to  the  process,  it  was  not  its  major 
determinant [76–79]. More recent data indicate a simpler role for the cPPT-CTS in promoting faster 
kinetics of reverse transcription [80]. This hypothesis is captivating, as lentiviral infection occurs in 
cells of low metabolism in which this process can be extremely long (such as myeloid cells). Thus, it is 
intriguing to speculate that this sequence may have evolved specifically in lentiviruses to maximize the 
speed at which reverse transcription is completed. In turn, fast completion of viral DNA synthesis may 
exert a protective effect on the viral genome for example by promoting its faster nuclear import, as 
suggested in [77,78], by contributing to structural rearrangements of VNCs or, more generally, by 
protecting it from cytoplasmic sensors that recognize RNA or single stranded DNA. In this respect, the 
cPPT-CTS has been recently shown to contribute to the protection of HIV-1 from members of the 
apolipoprotein  B  editing  catalytic  polypeptide  3  family  (APOBEC3s),  cytidine  deaminases  with 
marked antiviral activity [81–83]. These proteins are incorporated into virion particles where they 
deaminate single stranded viral DNA intermediates. Although APOBEC3s incorporation is countered 
by the viral protein Vif, residual molecules may escape Vif, especially in cells in which APOBEC3 
members are expressed at high levels. In this case, the cPPT-CTS element minimizes the time of 
exposure of single stranded DNA, thus providing an additional level of protection against APOBEC3 
proteins [81]. More generally, we do believe that the cPPT-CTS may exert a protective effect beyond 
APOBEC3s, because the advantage of lentiviral vectors bearing this sequence is manifest also in the 
absence  of  APOBEC3  proteins.  We  believe  it  likely  that  by  promoting  faster  kinetics  of  reverse 
transcription, the cPPT-CTS may indirectly protect the viral genome from multiple attacks brought by 
deaminases, but also by other endonucleases and yet unidentified cellular factors. 
If the above-mentioned viral elements contribute marginally to nuclear import, what are its true 
viral determinants? An important difference between the composition of VNCs obtained after lentiviral 
and  gammaretroviral  infection  is  their  content  in  Capsid  protein  (CA).  CA  is  the  main  structural 
component of viral cores within viral particles, but as soon as the virus accesses the cytoplasm of 
target cells, CA is progressively shed from VNCs. In the case of lentiviruses which are more apt for 
nuclear  import  than  gammaretroviruses,  this  loss  is  more  pronounced  [84–88].  Is  this  difference 
important for nuclear import? A role for CA in nuclear import is suggested by several findings: the 
existence of specific CA mutants that behave differently in cycling versus non-dividing cells, as well 
as the nuclear import defect of HIV chimeric viruses bearing gammaretroviral CA [89–93]. At present, 
a number of questions surround the role of CA in nuclear import. In particular, if CA associates with 
specific cellular transporters to reach the nucleus, why would loss of CA from viral cores be beneficial 
for this transport? On the other hand, if shedding of CA from the VNCs uncovers other signals that Viruses 2011, 3                                       
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mediate nuclear entry, which is the nature of these signals given that most of the components of VNCs 
have been found to play only a marginal role in this process? Does lentiviral CA promote a peculiar 
VNC trafficking  through which VNCs gain preferential access to the nucleus? More generally, is 
nuclear  import  governed  by  a  single  key  determinant  which  we  have  not  yet  found  by  multiple 
elements playing minor roles, or is it to be considered an overall promiscuous mechanism, as recently 
suggested in [94]? 
Despite  these  questions,  the  difference  in  the  extent  of  CA  shedding  from  VNCs  between 
lentiviruses and gammaretroviruses is compelling and suggests that VNCs reorganization may play a 
central role in nuclear import [92,95,96]. If this is true, a number of factors that affect the viral core 
stability and composition may indirectly influence nuclear import. One such factor may be reverse 
transcription itself that drives important structural changes in VNCs, or a structure such as the DNA 
flap, which may signal the end of the process [95,97]. From a strictly theoretical point of view, the 
possibility that the end of reverse transcription drives structural changes that enable the nuclear import 
of  VNCs  is  intriguing,  as  this  may  be  a  mechanism  to  favor  the  entry  of  completed  viral  DNA 
molecules into the nucleus [98]. 
The  above-mentioned  studies  focused  on  viral  proteins.  However,  several  studies  identified  
cellular  components  of  the  nucleo-cytoplasmic  transport  machinery  as  capable  of  modulating  
the  nuclear  import  of  HIV-1:  Nup85,  Nup107,  Nup133,  Nup153,  Nup155,  Nup160,  RanBP2, 
Transportin-SR2/TNPO3, importin alpha3 and Importin7 [99–103]. A direct interaction between these 
factors  and  viral  proteins  has  been  evidenced  only  in  the  case  of  Transportin-SR2/TNPO3  and 
Importin7  that  associate  with  IN  [104,105].  Although  multiple  evidence  indicates  that  these  two 
cellular proteins are involved in the nuclear import of HIV-1, the importance of IN during this step 
remains uncertain [106], as nuclear import occurs also in the absence of IN [78]. For the other cellular 
factors it remains unclear whether the role played in nuclear import is direct or indirect. In light of the 
functions  of  these  proteins  in  a  key  cellular  process  (nucleo-cytoplasmic  transport),  this  latter 
possibility cannot be excluded. 
2.3. The Conversion of a Lenti-Virus into a Lenti-Vector 
The concept of viral-based tools for gene delivery emerged for the first time in the early 1980s with 
vectors based on the Moloney Murine Leukaemia Virus (Mo-MLV) [107]. Vectors rely on the physical 
separation into different plasmids of proteins required for viral particle formation and infectivity (the 
packaging and the envelope constructs) and of cis-acting sequences sufficient to mobilize the viral 
genome (the transfer vector). The latter constitutes the core of the vector; a mini-viral genome devoid 
of viral open reading frames (ORFs), but carrying an expression cassette for the transgene of interest. 
As a consequence of the deletion of viral ORFs from the transfer vector, virions can undergo a single 
round of infection at the conclusion of which proviral DNA expresses only the transgene of interest. 
Among lentiviruses, HIV-1-based vectors were the first to be developed and gain wide usage for both 
fundamental and  applied purposes, so  that  our description shall  mostly  focus on  them  again  as  a 
paradigm for other lentiviral-derived vectors.  
The  first  gene  delivery  systems  used  replication-incompetent  HIV-1  vectors  to  study  different 
aspects of the viral life cycle in the early 1990s [108–113], but the key breakthrough came with the Viruses 2011, 3                                       
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construction  of  vectors  that,  in  contrast  to  MLV-derived  ones,  were  capable  of  transducing  
non-dividing neurons when injected into rat brains [75]. The first vector generation was made of three 
plasmids  in  which  the  packaging  functions  were  provided  by  an  Env-coding  plasmid  and  by  a 
packaging plasmid expressing all viral ORFs except Env under the control of a CMV promoter (in 
which of course the packaging sequence had been removed). The transfer vector was composed of an 
expression cassette framed by two wild type long terminal repeats (LTRs) and bearing sequences 
required  for  viral  RNA  export  in  producing  cells  (the  Rev-Responsive  Element,  RRE),  genome 
packaging  and  reverse  transcription  (Figure  1  and  Table  1).  In  the  second  generation  packaging 
vectors, most accessory genes were eliminated (vif, vpr, vpu and nef) and only Tat and Rev were 
retained [114], while in the third, Tat was also removed and Rev was provided on a fourth plasmid 
[115] (third generation vectors are based on four plasmids instead of three). In the case of transfer 
vectors, a number of modifications contributed to increase the performance of gene transfer, as for 
example the use of post transcriptional regulatory elements that enhance the transgene transcriptional 
expression as the human hepatitis virus post transcriptional element (HPRE) [116,117], or the use of 
heterologous polyadenylation enhancer elements, as those derived from simian virus 40 (SV40) or  
β-globin [118,119], or the use of different internal promoters to express a particular gene (or gene 
products, as shRNAs) of interest.  
Figure  1.  Evolution  of  lentiviral  vectors  based  on  HIV-1.  The  scheme  simplifies 
schematically  the  evolution  of  packaging  and  transfer  vectors.  In  the  case  of  transfer 
vectors, only three major evolutions have been depicted, despite the existence of a number 
of modifications that still today continue to ameliorate the vectors performance. LTR, long 
terminal repeat; SA and SD, splice acceptor and donor; RRE, Rev-responsive element. Rev 
associates to the RRE on viral genomic RNA and allows its export from the nucleus and its 
efficient incorporation into virion particles [182].  
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Table 1. Lentiviruses and lentiviral-derived vectors. *: HIV-2 is capable of inducing an 
immunodeficiency that mirrors the one induced by HIV-1, albeit with a prolonged delay 
from the initial infection. /-: SIVs do not cause disease in their natural host, but do so in 
monkeys of different species. #: BIV strains isolated from taurine cattle (Bos Taurus) are 
mostly apathogenic, while those isolated from Bali cattle (named also Jembrana disease 
virus, JDV, in Bos javanicus) induce an acute febrile illness. Vectors have been derived 
from  both.  The  main  references  are  provided  for  the  different  packaging  vector 
generations. NWM and OWM: new and old world monkeys. For simplicity, restriction has 
been ascribed to one or the other group, although certain species within each group may 
behave differently. NT: not tested. 
Virus  Host  Disease 
Vector Generation  Species Specific 
Restriction  1
st  2
nd  3
rd 
HIV-1  Human  Immunodeficiency 
[75,120]  [72,73,116]  [115] 
OWM, Rabbit, 
Cow 
HIV-2 
Human  Immunodeficiency * 
[158–164]  [165]   
OWM, Rabbit, 
Cow 
SIVSM  Monkey  Immunodeficiency /-  [166,167]  [166,168]  [168]  NWM, Cow 
SIVAGM  Monkey  Immunodeficiency /-  [169]      NWM 
EIAV 
Horses  Infectious anemia 
[170,171]  [172]  [172] 
OWM, Human, 
Rabbit, Cow 
FIV 
Cats  Immunodeficiency 
[173]  [174]  [174,175] 
OWM, Human, 
Rabbit, Cow 
VNV  Sheep  Pneumo-encephalitis    [176]    NT 
CAEV  Goat  Arthritis-encephalitis  [177]    [178]  NT 
BIV 
Cow  -/acute febrile illness
#  [179,180]  [181]  [181]  NT 
 
However, three major modifications have shaped the evolution of transfer vectors from their initial 
version [75]. The first is the substitution of the 5’ U3 viral promoter for a heterologous promoter to 
allow  the  Tat-independent  transcription  of  the  transfer  vector  [115,118,120,121].  The  second  is  a 
deletion of the enhancer/promoter sequence  of the 3’ U3 [115,118,120,121]. By the gymnastic of 
reverse transcription, this deleted 3’ U3 sequence is copied at both ends of proviral DNA resulting in a 
provirus that lacks a functional U3 viral promoter. This deletion, at the basis of self-inactivating (SIN) 
vectors, increases the safety of lentiviral vectors due to the lack of expression of ψ-bearing mRNAs in 
transduced cells and to the minimization of gene activation in the proximity of the provirus integration 
site  [122].  The  third  is  the  inclusion  of  the  cPPT-CTS  sequence  that  exerts  a  positive  effect  on 
transduction efficiency, despite controversies over its exact function [72,73,77,123]. 
Overall, the development of lentiviral vectors, that we have simplified here schematically, seeks to 
optimize  the  efficacy  of  gene  transfer,  while  eliminating  the  potential  dangers  due  to  the  use  of 
retroviral vectors. Examples of this constant optimization have been the development of third and 
fourth generation vectors that minimize considerably the risks of generation of replication-competent Viruses 2011, 3                                       
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recombinants (RCR), or the introduction of the SIN mutation that diminishes both the probability of 
RCR formation and impairs the promiscuous enhancer activity of the viral promoter.  
3. Additional Aspects of the Biology of Lentiviral Vectors for Particular Applications 
The  notions  outlined  above  have  been  at  the  basis  of  the  development  of  lentiviral  vectors. 
However, further efforts are ongoing to improve gene transfer, as for example those directed towards 
the targeting of specific cell types or the increase of the overall efficiency of transduction. These 
efforts aim at achieving the highest percentage of modified cells with the lowest viral input. Below, we 
will describe some of these ongoing efforts. 
3.1. Pseudotyping of Lentiviral Vectors 
Retroviral particles have an extraordinary ability to accommodate heterologous envelope proteins, 
and are referred to as pseudotyping, can acquire novel cellular tropism and intracellular behavior (for a 
review see [124]). Pseudotyping is common to all retroviruses, so that we will mostly outline here a 
few cases that are exclusive to lentiviruses in the transduction of quiescent and differentiated cells.  
The first property specified by envelope proteins is the type of cell recognized by the viral particle. 
In this respect, if pantropic envelopes, such as the vesicular stomatitis virus G protein (VSVg), are 
used to mediate viral entry into a wide variety of cells, more selective Envs must be employed for the 
specific targeting of a particular cell type in the midst of others. When possible, specificity can be 
achieved through the targeting of cellular receptors expressed uniquely on the cell type of interest. This 
is the case for the C-type lectin-like receptor (DC-SIGN) expressed almost exclusively on primary 
DCs [125]. An interesting step forward in the specific transduction of DCs has come through the 
modification of the envelope glycoprotein of the Sindbis virus. In its natural context this envelope is 
not specific, since it binds DC-SIGN on DCs, but also to heparan sulfate moieties present on most cell 
types. However, the removal of the heparan sulfate binding domain from the Sindbis virus envelope 
protein led to a modified glycoprotein that lost its ability to bind heparan sulfate but retained a strong 
DC-SIGN binding. Thus, this modification effectively restricted the tropism of pseudotyped lentiviruses 
(LVs) to DCs both ex vivo and in vivo [126]. Similar strategies may be applied to other cell types and 
may be particularly useful to reduce side effects due to widespread transgene expression [127]. 
A second property specified by some envelope proteins is the ability to influence steps that are 
subsequent to viral entry into target cells. For example, the infection of quiescent B and T cells is 
inefficient with VSVg-pseudotyped LVs. This is not due to a defect in viral entry, but rather to a 
restriction at the step of reverse transcription that is likely a consequence of the poor activation status 
of these cells [128]. Efficient transduction can be achieved upon cell activation, but this may not be an 
option in applications in which the preservation of a quiescent state is sought. To achieve efficient cell 
infection in the absence of major activation signals, a number of strategies have been developed that 
rely on artificially engineered envelopes and on envelopes other than VSVg. A common trait of these 
strategies is that envelope molecules, displayed at the surface of the viral particle, trigger an activation 
signal  upon  engagement  of  the  cellular  receptor.  This  activates  the  cell  transiently  and  allows  an 
efficient infection. The strategy has been successfully employed in the transduction of quiescent B and 
T cells using the Measles virus (MV) gp protein and cytokine-displaying LVs, respectively [129,130]. Viruses 2011, 3                                       
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In these cases, the intracellular signals conveyed upon the engagement of the signaling lymphocytic 
activation molecule receptor (SLAM) or of the specific cytokine receptor seem sufficient to promote 
LVs infection, at least transiently. A number of other viral particle-delivered signals are being explored 
and in the future we can expect a number of interesting developments along these lines. 
Finally,  certain  envelope  proteins  determine  a  peculiar  intracellular  behavior  of  VNCs  that  is 
particularly interesting, as in the case of the rabies G protein that endows pseudotyped particles with 
the same properties of the rabies virus, namely the ability to undergo retrograde transport along the 
cell’s axons. This extraordinary property has been used for the transduction of motor neurons in an 
animal study for the amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. In 
this study, EIAV-derived lentiviral vectors were pseudotyped with the rabies G protein and injected in 
limb muscles of mice [131] where, thanks to their envelope, they were able to transduce motor neurons 
of the central nervous system [132]. The possibility of taking advantage of retrograde transport to 
achieve neuron transduction from the periphery is extremely attractive for gene therapy applications of 
the CNS, since this strategy is less invasive than the direct modification of the CNS.  
In conclusion, envelope proteins not only specify the type of cells that are recognized by the viral 
particle, but can also influence the subsequent behavior of the virus inside the cell. In some instances, 
this  contributes  to  remove  some  of  the  post-entry  obstacles  that  can  be  encountered  during  the 
transduction of a particular cell type.  
3.2. Manipulation of Viral Non-Structural Proteins to Promote Cell Type Specific Targeting: The Case 
of the SIVSM/HIV-2 Vpx Protein and Myeloid Cells 
A further possibility to act on the specificity of LV transduction may come from the use of viral 
proteins that affect the early phases of infection in a cell type dependent manner. One example in this 
direction is provided by the Vpx protein. Vpx is coded by members of the SIVSM/HIV-2 lineage, but is 
absent in most of the remaining lineages of primate lentiviruses. Vpx is a nonstructural viral protein 
that is incorporated into viral particles and is thus present during the early phases of infection, where it 
exerts a positive effect on the process of reverse transcription [133–137]. An interesting feature of the 
action of Vpx is its cell type specificity that is restricted to cells of the myeloid lineage. The exact 
mechanism  underlying  the  positive  effect  of  Vpx  on  lentiviral  transduction  is  currently  under 
investigation.  However,  multiple  lines  of  evidence  suggest  that  Vpx  may  act  by  counteracting  a 
restriction factor specifically expressed in myeloid cells, thus explaining its cell type specific effect 
[134,138]. Vpx displays two phenotypes that may be of interest for gene therapy purposes. First, it is 
absolutely required for the infection of myeloid cells with parental SIVSM or HIV-2 viruses, while it is 
dispensable for the infection of other cell types, such as lymphocytes [139]. Second, when provided 
onto  recipient  cells  at  the  moment  of  infection,  it  increases  the  efficiency  of  transduction  of 
heterologous lentiviral vectors (as HIV-1 and FIV) by at least ten-fold, an effect that is again specific 
to myeloid cells [133,140]. As a consequence, one can imagine that SIVSM or HIV-2 vectors devoid of 
Vpx could be used to transduce preferentially peripheral blood lymphocytes in the blood as opposed to 
monocytes or circulating DCs, thus diminishing anti vector/transgene responses mediated by these 
antigen presenting cells. Conversely, in applications in which specific transduction of myeloid cells is 
required, lentiviral vectors (derived from HIV-1, but also FIV and EIAV) may be used together with Viruses 2011, 3                                       
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Vpx, since this will improve their performance specifically in these cells. As a consequence, efficient 
cell transduction can be achieved even at low viral inputs [133,140], thus avoiding large viral doses 
that  in  some  instances  have  been  shown  to  be  detrimental  to  the  physiology  of  modified  cells 
[141,142].  For  the  moment,  Vpx  constitutes  the  sole  example  of  non-structural  viral  protein  that 
affects, to such a large extent, the efficiency of the early phases of infection in a setup of interest for 
gene therapy. It is possible that other lentiviral proteins exert other interesting effects that could be 
similarly  exploited,  but  whether  this  is  the  case  remains  unknown  at  present.  In  the  future, 
combinations between specific envelope proteins, viral proteins that have cell type specific properties, 
and the use of cell type specific promoters, may be particularly potent in promoting the selectivity of 
the gene transfer process.  
4. Particular Considerations on the Use of Lentiviral Vectors  
4.1. The Problem of Cross-Species Usage of Lentiviral Vectors: The Tripartite Motif 5α Protein 
Cells possess several intrinsic  defense  mechanisms against pathogens. The key determinant  for 
these defenses  is the recognition of features that are shared by classes of pathogens, or  pathogen 
associated molecular patterns (PAMPs). For retroviruses, two key features are the reverse transcription 
process  and  viral  capsids  that  can  be  truly  defined  as  PAMPs.  These  are  recognized  by  two 
prototypical antiviral factors: by members of the APOBEC3 family and by the Tripartite motif 5α 
protein (TRIM5α), respectively [143,144]. For gene therapy purposes, the classical antiviral effect of 
APOBEC3s may be neglected using virus-producing cells in which these proteins are absent, as 293T 
cells. However, the same is not true for TRIM5α that recognizes incoming viral particles in target cells 
[145–147].  TRIM5α  proteins  recognize  incoming  VNCs  via  CA,  triggering  their  premature 
disassembly and thus impairing reverse transcription and infection [148]. It is unclear whether this 
process  involves  direct  degradation  of  viral  components  and/or  trafficking  of  VNCs,  in  particular 
intracellular locations [149,150], but the result of this impairment can be particularly strong (from 2–3 
to 100 fold in a single round infection) (reviewed in [151]). As a general rule, viruses that thrive in one 
species  are  not  recognized  by  the  TRIM5α  ortholog  of  that  species.  This  is  intuitive;  to  succeed 
infection a virus must have evolved to bypass this block. On the other hand, TRIM5α orthologs act as a 
potent barrier in cross-species transmission and can antagonize viruses, and thus vectors, of different 
species as summarized in Table I [152–157]. Thus, the TRIM5α effect must be carefully weighted 
when  using  LVs  derived  from  different  species,  considering  that  even  a  moderate  inhibition  by 
TRIM5α may considerably reduce the proportion of successfully transduced cells. One of the features 
of the restriction mediated by  TRIM5α is the fact that it can  be saturated with high viral inputs. 
Generally, saturation is observed within the high viral doses used in gene therapy, suggesting that 
infection  could  be  achieved  with  LVs  of  different  species  even  in  the  presence  of  a  restricting 
TRIM5α. However in this case, the need to saturate TRIM5 with high viral inputs may contrast with 
the requirement to use low viral doses to minimize modifications of the cell physiology or to diminish 
immune responses directed against the vector [141,142]. In cells exquisitely susceptible to the presence 
of  pathogens,  such  as  myeloid  cells,  a  correct  balancing  between  the  requirement  for  efficient  Viruses 2011, 3                                       
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cell  modification  and  the  need  to  avoid  gross  modifications  of  the  cell  physiology  may  be  
particularly important.  
4.2. The Yin and the Yang of Integration 
Although the main interest of retroviral vectors for gene therapy purposes lays in the integration of 
their genome, this very feature is intrinsically dangerous. The potential drawbacks of integration have 
not received much attention in the past, probably because no adverse effects had been observed in 
retroviral-mediated gene therapy trials started more than two decades ago (as, for example, in the 
severe combined immunodeficiency syndrome due to a deficiency in the adenosine deaminase enzyme, 
SCID-ADA, [183]). However, serious side effects were observed in a proportion of SCID-γC patients 
undergoing  retroviral  mediated  gene  replacement.  The  SCID-γC  syndrome  is  a  lethal 
immunodeficiency in which T cells cannot develop due to the absence of the γC gene and the gene 
therapy approach in this trial consisted of a simple gene replacement in hematopoietic stem cells. The 
results of this clinical trial best illustrate the benefits and the potential dangers linked to retroviral 
mediated  gene  therapy. On one  hand,  the gene replacement  trial  was a  success because  modified 
hematopoietic stem cells functionally replenished the patients’ immune system and about half of the 
patients maintained the use of immune functions for over 10 years. On the other hand, a proportion of 
patients  developed  leukemia  as  a  consequence  of  the  deregulated  expression  of  proto-oncogenes 
adjacent to the retroviral vector integration sites [184]. 
This  finding  spurred  a  series  of  studies  on  the  features  that  govern  retroviral  integration  on  a 
genome wide scale. These studies revealed that retroviral integrases display strong differences in the 
selection  of  chromosomal  integration  sites  (in  active  transcriptional  units  for  HIV-1  and  close  to 
transcriptional start sites for MLV) [185,186]. In the case of HIV-1, a further bias toward regions 
containing recognition sequences for cellular co-factors that associate to IN, such as the lens epithelial 
growth factor p75, (LEDGF) has also been described [187]. LEDGF is a cellular DNA binding factor 
that associates to HIV-1 IN and that is required for viral DNA integration [188,189]. It is thus not 
surprising that HIV-1 integration favors sites in which LEDGF is enriched.  
Overall, these studies highlighted the fact that in its natural configuration, the integration process is 
largely stochastic and that the result of integration may just as likely be with or without consequences. 
This is shown by the different outcomes observed in patients participating in the same clinical trial, as 
well as by the findings that particular chromosomal features are preferentially, but not exclusively, 
selected during integration [185,186].  
To more selectively target proviral DNA integration, a number of efforts are now being directed 
either at engineering modified IN fused to well characterized heterologous DNA binding domains or at 
modifying IN-associated cellular co-factors [190–192]. The efforts to achieve site directed retroviral 
integration, or chosen integration, are at their infancy and for the moment the results obtained are 
rather disappointing because of the relative abundance of similar DNA binding sites spread over the 
genome.  To  date,  a  single  virus  has  been  shown  to  be  capable  of  site  specific  integration:  the 
adeno-associated  virus  (AAV)  that  integrates  a  small  fraction  of  its  genomes  into  the  human 
chromosome 19q13.42 (although more recent data seems to question this specificity, [193,194]. The 
specificity of this integration is mediated by the Rep 78/68 proteins that recognize a sequence called Viruses 2011, 3                                       
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AAVS1 that is present both on the viral genome and in this region of the human genome. Future 
strategies  aimed at directing  retroviral  integration  may  possibly take  advantage  of the  mechanism 
provided by this virus and transpose it to lentiviruses. Alternatively, site specific integration may be 
achieved by engineering IN fusion proteins to meganucleases; DNA nucleases that have the peculiarity 
to recognize long, and thus rarer, DNA binding sequences that can be theoretically present only once 
in the human genome [195,196]. Whether these approaches are feasible remains to be determined. 
4.3. Non-Integrative Lentiviral Vectors 
An  alternative  strategy  to  circumvent  the  negative  effects  of  integration,  is  represented  by 
non-integrative  LVs  that  have  been  developed  by  a  number  of  laboratories  [197–200].  These  are 
vectors bearing inactivating mutations in IN that inhibit the integration of viral DNA [198,201,202]. 
During the early phases of infection, viral DNA can either integrate into the host genome or exist in the 
form of episomal DNA bearing one or two long terminal repeats (the so called 1 and 2LTRs circles). 
These episomes originate in the nucleus upon viral ends joining by cellular ligases (2LTRs), or through 
the recombination of the two identical ends (1LTRs). Both forms are competent for gene expression in 
their natural context (for example during wild type HIV-1 infection) [203], as well as in the context of 
lentiviral vectors. However, due to their lack of origin of replication, these episomes are gradually lost 
during  cell  division.  On  the  contrary,  viral  DNA  episomes  are  stable  in  non-dividing  cells,  the 
preferred targets for lentiviral mediated transduction. Thus, non-integrative LVs could provide a safe 
setting in gene delivery at least in non-dividing or differentiated cells.  
5. Conclusions and Perspectives 
Lentiviral vectors bears an obvious advantage over other retroviral vectors in that they offer the 
possibility to efficiently target non-dividing and differentiated cells, such as DCs or neurons. As such, 
these vectors are of extreme interest for a multitude of gene therapy applications. Although the basics 
of retroviral and lentiviral vectors are now firmly established, specific applications require careful 
tailoring of several elements to ameliorate the efficiency of gene transfer. Indeed, the transduction of 
non-dividing cells cannot be resumed to the mere phase of nuclear import,  and several additional 
obstacles are encountered by viral vectors in a number of differentiated and quiescent cell types. In 
some  instances,  these  barriers  can  be  overcome  through  the  use  of  envelope  proteins  conferring 
particular properties to the vector or that transiently stimulate the target cells. In others, the same goal 
can be achieved through the use of viral elements that facilitate transduction of the particular cell type 
of interest.  
Paradoxically,  the  use  of  retroviral  vectors  is  hindered  by  the  same  process  that  makes  them 
interesting for gene therapy, i.e., integration. This process is largely nonspecific and, as it has been 
shown in vivo, may either be of no consequence to the cell or lead to serious drawbacks. Although this 
problem may in theory be minimized in gene therapy applications targeting terminally differentiated 
cells, the problem of integration is serious. To this end, a number of alternative strategies have been 
developed, ranging from the redirection of retroviral integration to particular chromosomal locations, 
to the ablation of the integration process altogether. Although in its infancy, the efforts to redirect 
retroviral  integration  must  be  pursued  and  researchers  may  possibly  transpose  to  lentiviruses  a Viruses 2011, 3                                       
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mechanism  of  specific  integration  used  by  other  viruses.  As  in  the  past,  all  the  ameliorations  of 
lentiviral vectors will be the fruitful transposition of basic research discoveries in virology to the field 
of gene therapy.  
Acknowledgements 
We do apologize to those authors whose work has not been cited here. We are conscious that this 
review may have deserted important work and aspects in the field, despite our efforts to minimize this 
possibility. Work in our laboratory is supported by grants from the Agence Nationale de Recherche sur 
le SIDA (ANRS), SIDACTION, INSERM and Ecole Normale Supérieure de Lyon (ENS-Lyon). S.D. 
is a post-doctoral fellow of the ANRS. A.C. is supported by the Centre National de la Recherche 
Sciéntifique (CNRS). The authors have no conflicting financial interests. 
References and Notes 
1.  Campbell, R.S.; Robinson, W.F. The comparative pathology of the lentiviruses. J. Comp. Pathol. 
1998, 119, 333–395. 
2.  Leroux, C.; Cadore, J.L.; Montelaro, R.C. Equine Infectious Anemia Virus (EIAV): What has 
HIV's country cousin got to tell us? Vet. Res. 2004, 35, 485–512. 
3.  Gottlieb, M.S.; Schroff, R.; Schanker, H.M.; Weisman, J.D.; Fan, P.T.; Wolf, R.A.; Saxon, A. 
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: 
Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981, 305, 1425–1431. 
4.  Masur, H.; Michelis, M.A.; Greene, J.B.; Onorato, I.; Stouwe, R.A.; Holzman, R.S.; Wormser, G.; 
Brettman, L.; Lange, M.; Murray, H.W.; Cunningham-Rundles, S. An outbreak of community-
acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. 
N. Engl. J. Med. 1981, 305, 1431–1438. 
5.  Siegal,  F.P.;  Lopez,  C.;  Hammer,  G.S.;  Brown,  A.E.;  Kornfeld,  S.J.;  Gold,  J.;  Hassett,  J.; 
Hirschman,  S.Z.;  Cunningham-Rundles,  C.;  Adelsberg,  B.R.;  et  al.  Severe  acquired 
immunodeficiency  in  male  homosexuals,  manifested  by  chronic  perianal  ulcerative  herpes 
simplex lesions. N. Engl. J. Med. 1981, 305, 1439–1444. 
6.  Shaw, G.M.; Hahn, B.H.; Arya, S.K.; Groopman, J.E.; Gallo, R.C.; Wong-Staal, F. Molecular 
characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune 
deficiency syndrome. Science 1984, 226, 1165–1171. 
7.  Clavel,  F.;  Guetard,  D.;  Brun-Vezinet,  F.;  Chamaret,  S.;  Rey,  M.A.;  Santos-Ferreira,  M.O.; 
Laurent, A.G.; Dauguet, C.; Katlama, C.; Rouzioux, C.; et al. Isolation of a new human retrovirus 
from West African patients with AIDS. Science 1986, 233, 343–346. 
8.  Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, 
C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a 
T-lymphotropic  retrovirus  from  a  patient  at  risk  for  acquired  immune  deficiency  syndrome 
(AIDS). Science 1983, 220, 868–871. 
9.  Mir,  K.D.;  Gasper,  M.A.;  Sundaravaradan,  V.;  Sodora,  D.L.  SIV  infection  in  natural  hosts: 
Resolution of immune activation during the acute-to-chronic transition phase. Microbes Infect. 
2010, 1, 14–24. Viruses 2011, 3                                       
 
 
147 
10.  Pandrea, I.; Apetrei,  C.  Where  the wild things  are:  Pathogenesis of SIV infection in  African 
nonhuman primate hosts. Curr. HIV/AIDS Rep. 2010, 7, 28–36. 
11.  Pandrea, I.; Sodora, D.L.; Silvestri, G.; Apetrei, C. Into the wild: Simian immunodeficiency virus 
(SIV) infection in natural hosts. Trends Immunol. 2008, 29, 419–428. 
12.  Brenchley,  J.M.;  Silvestri,  G.;  Douek,  D.C.  Nonprogressive  and  progressive  primate 
immunodeficiency lentivirus infections. Immunity 2010, 32, 737–742. 
13.  Silvestri, G. AIDS pathogenesis: A tale of two monkeys. J. Med. Primatol. 2008, 37, 6–12. 
14.  Troyer,  J.L.;  Vandewoude,  S.;  Pecon-Slattery,  J.;  McIntosh,  C.;  Franklin,  S.;  Antunes,  A.; 
Johnson,  W.;  O’Brien,  S.J.  FIV  cross-species  transmission:  An  evolutionary  prospective.  
Vet. Immunol. Immunopathol. 2008, 123, 159–166. 
15.  Sigurdsson, B.; Grimsson, H.; Palsson, P.A. Maedi, a chronic, progressive infection of sheep’s 
lungs. J. Infect. Dis. 1952, 90, 233–241. 
16.  Sigurdsson, B.; Palsson, P.A.; Tryggvaddottir, A. Transmission experiments with maedi. J. Infect. 
Dis. 1953, 93, 166–175. 
17.  Desport,  M.;  Lewis,  J.  Jembrana  disease  virus:  Host  responses,  viral  dynamics  and  disease 
control. Curr. HIV Res. 2010, 8, 53–65. 
18.  Egberink, H.; Horzinek, M.C. Animal immunodeficiency viruses. Vet. Microbiol. 1992, 33, 311–331. 
19.  Ziegler-Heitbrock, H.W. The biology of the monocyte system. Eur. J. Cell. Biol. 1989, 49, 1–12. 
20.  Leon,  B.;  Ardavin,  C.  Monocyte-derived  dendritic  cells  in  innate  and  adaptive  immunity. 
Immunol. Cell. Biol. 2008, 86, 320–324. 
21.  Robbins,  C.S.;  Swirski,  F.K.  The  multiple  roles  of  monocyte  subsets  in  steady  state  and 
inflammation. Cell. Mol. Life Sci. 2010, 67, 2685–2693. 
22.  Mantovani, A.; Sica, A.; Locati, M. Macrophage polarization comes of age. Immunity 2005, 23, 
344–346. 
23.  Martinez, F.O. The transcriptome of human monocyte subsets begins to emerge. J. Biol. 2009, 8, 99. 
24.  Sanchez-Torres,  C.;  Garcia-Romo,  G.S.;  Cornejo-Cortes,  M.A.;  Rivas-Carvalho,  A.;  Sanchez-
Schmitz, G. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic 
cells with different abilities to stimulate CD4+ T cells. Int. Immunol. 2001, 13, 1571–1581. 
25.  Stec, M.; Weglarczyk, K.; Baran, J.; Zuba, E.; Mytar, B.; Pryjma, J.; Zembala, M. Expansion and 
differentiation of CD14+CD16(-) and CD14+ +CD16+ human monocyte subsets from cord blood 
CD34+ hematopoietic progenitors. J. Leukoc. Biol. 2007, 82, 594–602. 
26.  van de Veerdonk, F.L.; Netea, M.G. Diversity: A hallmark of monocyte society. Immunity 2010, 
33, 289–291. 
27.  Crowe, S.M.; Ziegler-Heitbrock, L. Editorial: Monocyte subpopulations and lentiviral infection.  
J. Leukoc. Biol. 2010, 87, 541–543. 
28.  Dawson, M. Pathogenesis of maedi-visna. Vet. Rec. 1987, 120, 451–454. 
29.  Gendelman,  H.E.;  Narayan,  O.;  Molineaux,  S.;  Clements,  J.E.;  Ghotbi,  Z.  Slow,  persistent 
replication  of  lentiviruses:  Role  of  tissue  macrophages  and  macrophage  precursors  in  bone 
marrow. Proc. Natl. Acad. Sci. U. S. A. 1985, 82, 7086–7090. 
30.  Meltzer,  M.S.;  Skillman,  D.R.;  Gomatos,  P.J.;  Kalter,  D.C.;  Gendelman,  H.E.  Role  of 
mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. 
Rev. Immunol. 1990, 8, 169–194. Viruses 2011, 3                                       
 
 
148 
31.  Maury, W. Monocyte maturation controls expression of equine infectious anemia virus. J. Virol. 
1994, 68, 6270–6279. 
32.  Sellon,  D.C.;  Perry,  S.T.;  Coggins,  L.;  Fuller,  F.J.  Wild-type  equine  infectious  anemia  virus 
replicates  in  vivo  predominantly  in  tissue  macrophages,  not  in  peripheral  blood  monocytes.  
J. Virol. 1992, 66, 5906–5913. 
33.  Adeyemo, O.; Gao, R.J.; Lan, H.C. Cytokine production in vitro by macrophages of goats with 
caprine arthritis-encephalitis. Cell. Mol. Biol. (Noisy-le-grand) 1997, 43, 1031–1037. 
34.  Magnani, M.; Rossi, L.; Fraternale, A.; Silvotti, L.; Quintavalla, F.; Piedimonte, G.; Matteucci, 
D.;  Baldinotti,  F.;  Bendinelli,  M.  Feline  immunodeficiency  virus  infection  of  macrophages:  
In vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes. AIDS Res. 
Hum. Retroviruses 1994, 10, 1179–1186. 
35.  Mizukoshi,  F.;  Baba,  K.;  Horiuchi,  H.;  Goto-Koshino,  Y.;  Setoguchi-Mukai,  A.;  Fujino,  Y.; 
Ohno, K.; Moore, P.F.; Tsujimoto, H. Characterization of monocyte-derived dendritic cells from 
cats infected with feline immunodeficiency virus. J. Vet. Med. Sci. 2009, 71, 865–871. 
36.  Clabough, D.L.; Gebhard, D.; Flaherty, M.T.; Whetter, L.E.; Perry, S.T.; Coggins, L.; Fuller, F.J. 
Immune-mediated  thrombocytopenia  in  horses  infected  with  equine  infectious  anemia  virus.  
J. Virol. 1991, 65, 6242–6251. 
37.  Asin, S.N.; Fanger, M.W.; Wildt-Perinic, D.; Ware, P.L.; Wira, C.R.; Howell, A.L. Transmission 
of HIV-1 by primary human uterine epithelial cells and stromal fibroblasts. J. Infect. Dis. 2004, 
190, 236–245. 
38.  David, S.A.; Smith, M.S.; Lopez, G.J.; Adany, I.; Mukherjee, S.; Buch, S.; Goodenow, M.M.; 
Narayan, O. Selective transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ 
T cells. AIDS Res. Hum. Retroviruses 2001, 17, 59–68. 
39.  Meng,  G.;  Wei,  X.;  Wu,  X.;  Sellers,  M.T.;  Decker,  J.M.;  Moldoveanu,  Z.;  Orenstein,  J.M.; 
Graham, M.F.; Kappes, J. C.; Mestecky, J.; Shaw, G.M.; Smith, P.D. Primary intestinal epithelial 
cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat. Med. 2002, 8, 150–156. 
40.  Satomi,  M.;  Shimizu,  M.;  Shinya,  E.;  Watari,  E.;  Owaki,  A.;  Hidaka,  C.;  Ichikawa,  M.;  
Takeshita,  T.;  Takahashi,  H.  Transmission  of  macrophage-tropic  HIV-1  by  breast-milk 
macrophages via DC-SIGN. J. Infect. Dis. 2005, 191, 174–181. 
41.  Bangham,  C.R.  Retrovirus  infections  of  the  nervous  system.  Curr.  Opin.  Neurol.  Neurosurg. 
1993, 6, 176–181. 
42.  Krebs,  F.C.;  Ross,  H.;  McAllister,  J.;  Wigdahl,  B.  HIV-1-associated  central  nervous  system 
dysfunction. Adv. Pharmacol. 2000, 49, 315–385. 
43.  Gras, G.; Kaul, M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 
infection. Retrovirology 2010, 7, 30. 
44.  Zink, M.C.; Narayan, O.; Kennedy, P.G.; Clements, J.E. Pathogenesis of visna/maedi and caprine 
arthritis-encephalitis: New leads on the mechanism of restricted virus replication and persistent 
inflammation. Vet. Immunol. Immunopathol. 1987, 15, 167–180. 
45.  Clements, J.E.; Gabuzda, D.H.; Gdovin, S.L. Cell type specific and viral regulation of visna virus 
gene expression. Virus Res. 1990, 16, 175–183. Viruses 2011, 3                                       
 
 
149 
46.  Gabuzda, D.H.; Hess, J.L.; Small, J.A.; Clements, J.E. Regulation of the visna virus long terminal 
repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites. Mol. 
Cell. Biol. 1989, 9, 2728–2733. 
47.  Haase, A.T. Pathogenesis of lentivirus infections. Nature 1986, 322, 130–136. 
48.  Peluso, R.; Haase, A.; Stowring, L.; Edwards, M.; Ventura, P. A Trojan Horse mechanism for the 
spread of visna virus in monocytes. Virology 1985, 147, 231–236. 
49.  Arfi, V.; Riviere, L.; Jarrosson-Wuilleme, L.; Goujon, C.; Rigal, D.; Darlix, J.L.; Cimarelli, A. 
Characterization  of  the  early  steps  of  infection  of  primary  blood  monocytes  by  human 
immunodeficiency virus type 1. J. Virol. 2008, 82, 6557–6565. 
50.  Sedaghat, A.R.; Siliciano, R.F.; Wilke, C.O. Constraints on the dominant mechanism for HIV 
viral dynamics in patients on raltegravir. Antivir. Ther. 2009, 14, 263–271. 
51.  O'Brien, W.A.; Namazi, A.; Kalhor, H.; Mao, S.H.; Zack, J.A.; Chen, I.S. Kinetics of human 
immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed 
by limitations of nucleotide precursors. J. Virol. 1994, 68, 1258–1263. 
52.  Eisert, V.; Kreutz, M.; Becker, K.; Konigs, C.; Alex, U.; Rubsamen-Waigmann, H.; Andreesen, 
R.;  von  Briesen,  H.  Analysis  of  cellular  factors  influencing  the  replication  of  human 
immunodeficiency virus type I in human macrophages derived from blood of different healthy 
donors. Virology 2001, 286, 31–44. 
53.  Sonza, S.; Maerz, A.; Deacon, N.; Meanger, J.; Mills, J.; Crowe, S. Human immunodeficiency 
virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated 
peripheral blood monocytes. J. Virol. 1996, 70, 3863–3869. 
54.  Redel, L.; Le Douce, V.; Cherrier, T.; Marban, C.; Janossy, A.; Aunis, D.; Van Lint, C.; Rohr, O.; 
Schwartz, C. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T 
lymphocytes. J. Leukoc. Biol. 2010, 87, 575–588. 
55.  Pincha,  M.;  Sundarasetty,  B.S.;  Stripecke,  R.  Lentiviral  vectors  for  immunization:  An 
inflammatory field. Expert Rev. Vaccine. 2010, 9, 309–321. 
56.  Smits, E.L.; Anguille, S.; Cools, N.; Berneman, Z.N.; Van Tendeloo, V.F. Dendritic cell-based 
cancer gene therapy. Hum. Gene Ther. 2009, 20, 1106–1118. 
57.  Lusk, C.P.; Blobel, G.; King, M.C. Highway to the inner nuclear membrane: Rules for the road. 
Nat. Rev. Mol. Cell Biol. 2007, 8, 414–420. 
58.  Jarrosson-Wuilleme,  L.;  Goujon,  C.;  Bernaud,  J.;  Rigal,  D.;  Darlix,  J.L.;  Cimarelli,  A. 
Transduction of nondividing human macrophages with gammaretrovirus-derived vectors. J. Virol. 
2006, 80, 1152–1159. 
59.  Katz,  R.A.;  Greger,  J.G.;  Darby,  K.;  Boimel,  P.;  Rall,  G.F.;  Skalka,  A.M.  Transduction  of 
interphase cells by avian sarcoma virus. J. Virol. 2002, 76, 5422–5434. 
60.  Greger,  J.G.;  Katz,  R.A.;  Taganov,  K.;  Rall,  G.F.;  Skalka,  A.M.  Transduction  of  terminally 
differentiated neurons by avian sarcoma virus. J. Virol. 2004, 78, 4902–4906. 
61.  Mergia, A.; Chari, S.; Kolson, D.L.; Goodenow, M.M.; Ciccarone, T. The efficiency of simian 
foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 2001, 280, 
243–252. 
62.  Fassati, A. HIV infection of non-dividing cells: A divisive problem. Retrovirology 2006, 3, 74. 
63.  Bukrinsky, M. A hard way to the nucleus. Mol. Med. 2004, 10, 1–5. Viruses 2011, 3                                       
 
 
150 
64.  Yamashita,  M.;  Emerman,  M.  Retroviral  infection  of  non-dividing  cells:  Old  and  new 
perspectives. Virology 2006, 344, 88–93. 
65.  Bukrinsky, M.I.; Haffar, O.K. HIV-1 nuclear import: In search of a leader. Front. Biosci. 1999, 4, 
D772–D781. 
66.  Goldfarb, D.S. HIV-1 virology. Simply Marvelous nuclear transport. Curr. Biol. 1995, 5, 570–573. 
67.  Stevenson, M. HIV nuclear import: What’s the flap? Nat. Med. 2000, 6, 626–628. 
68.  Harris, J.D.; Scott, J.V.; Traynor, B.; Brahic, M.; Stowring, L.; Ventura, P.; Haase, A.T.; Peluso, 
R. Visna virus DNA: Discovery of a novel gapped structure. Virology 1981, 113, 573–583. 
69.  Kupiec,  J.J.;  Tobaly-Tapiero,  J.;  Canivet,  M.;  Santillana-Hayat,  M.;  Flugel,  R.M.;  Peries,  J.; 
Emanoil-Ravier, R. Evidence for a gapped linear duplex DNA intermediate in the replicative 
cycle of human and simian spumaviruses. Nucleic Acids Res. 1988, 16, 9557–9565. 
70.  Heyman, T.; Agoutin, B.; Friant, S.; Wilhelm, F.X.; Wilhelm, M.L. Plus-strand DNA synthesis of 
the yeast retrotransposon Ty1 is initiated at two sites, PPT1 next to the 3' LTR and PPT2 within 
the pol gene. PPT1 is sufficient for Ty1 transposition. J. Mol. Biol. 1995, 253, 291–303. 
71.  Peters, K.; Barg, N.; Gartner, K.; Rethwilm, A. Complex effects of foamy virus central purine-
rich regions on viral replication. Virology 2008, 373, 51–60. 
72.  Follenzi, A.; Ailles, L.E.; Bakovic, S.; Geuna, M.; Naldini, L. Gene transfer by lentiviral vectors 
is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 2000, 25, 
217–222. 
73.  Sirven,  A.;  Pflumio,  F.;  Zennou,  V.;  Titeux,  M.;  Vainchenker,  W.;  Coulombel,  L.;  Dubart-
Kupperschmitt, A.; Charneau, P. The human immunodeficiency virus type-1 central DNA flap is 
a  crucial  determinant  for  lentiviral  vector  nuclear  import  and  gene  transduction  of  human 
hematopoietic stem cells. Blood 2000, 96, 4103–4110. 
74.  Zennou, V.; Petit, C.; Guetard, D.; Nerhbass, U.; Montagnier, L.; Charneau, P. HIV-1 genome 
nuclear import is mediated by a central DNA flap. Cell 2000, 101, 173–185. 
75.  Naldini, L.; Blomer, U.; Gallay, P.; Ory, D.; Mulligan, R.; Gage, F.H.; Verma, I.M.; Trono, D.  
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 
1996, 272, 263–267. 
76.  Limon,  A.;  Nakajima,  N.;  Lu,  R.;  Ghory,  H.Z.;  Engelman,  A.  Wild-type  levels  of  nuclear 
localization and human immunodeficiency virus type 1 replication in the absence of the central 
DNA flap. J. Virol. 2002, 76, 12078–12086. 
77.  Van Maele, B.; De Rijck, J.; De Clercq, E.; Debyser, Z. Impact of the central polypurine tract on 
the kinetics of human immunodeficiency virus type 1 vector transduction.  J. Virol. 2003, 77, 
4685–4694. 
78.  Riviere, L.; Darlix,  J.L.;  Cimarelli, A. Analysis  of the viral  elements  required in the nuclear 
import of HIV-1 DNA. J. Virol. 2010, 84, 729–739. 
79.  Dvorin, J.D.; Bell, P.; Maul, G.G.; Yamashita, M.; Emerman, M.; Malim, M.H. Reassessment of 
the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear 
import. J. Virol. 2002, 76, 12087–12096. 
80.  Skasko, M.; Kim, B. Compensatory role of human immunodeficiency virus central polypurine 
tract sequence in kinetically disrupted reverse transcription. J. Virol. 2008, 82, 7716–7720. Viruses 2011, 3                                       
 
 
151 
81.  Hu, C.; Saenz, D.T.; Fadel, H.J.; Walker, W.; Peretz, M.; Poeschla, E.M. The HIV-1 central 
polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 2010, 84, 
11981–11993. 
82.  Suspene, R.; Rusniok, C.; Vartanian, J.P.; Wain-Hobson, S. Twin gradients in APOBEC3 edited 
HIV-1  DNA  reflect  the  dynamics  of  lentiviral  replication.  Nucleic  Acids  Res.  2006,  34,  
4677–4684. 
83.  Wurtzer, S.; Goubard, A.; Mammano, F.; Saragosti, S.; Lecossier, D.; Hance, A.J.; Clavel, F. 
Functional  central  polypurine  tract  provides  downstream  protection  of  the  human 
immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J. Virol. 
2006, 80, 3679–3683. 
84.  Farnet,  C.M.;  Haseltine,  W.A.  Determination  of  viral  proteins  present  in  the  human 
immunodeficiency virus type 1 preintegration complex. J. Virol. 1991, 65, 1910–1915. 
85.  Bowerman, B.; Brown, P.O.; Bishop, J.M.; Varmus, H.E. A nucleoprotein complex mediates the 
integration of retroviral DNA. Genes Dev. 1989, 3, 469–478. 
86.  Fassati,  A.;  Goff,  S.P.  Characterization  of  intracellular  reverse  transcription  complexes  of 
Moloney murine leukemia virus. J. Virol. 1999, 73, 8919–8925. 
87.  Fassati, A.; Goff, S. P. Characterization of intracellular reverse transcription complexes of human 
immunodeficiency virus type 1. J. Virol. 2001, 75, 3626–3635. 
88.  Miller, M.D.; Farnet, C.M.; Bushman, F.D. Human immunodeficiency virus type 1 preintegration 
complexes: Studies of organization and composition. J. Virol. 1997, 71, 5382–5390. 
89.  Yamashita,  M.;  Emerman,  M.  Capsid  is  a  dominant  determinant  of  retrovirus  infectivity  in 
nondividing cells. J. Virol. 2004, 78, 5670–5678. 
90.  Yamashita,  M.;  Emerman,  M.  Cellular  restriction  targeting  viral  capsids  perturbs  human 
immunodeficiency virus type 1 infection of nondividing cells. J. Virol. 2009, 83, 9835–9843. 
91.  Yamashita, M.; Perez, O.; Hope, T.J.; Emerman, M. Evidence for direct involvement of the capsid 
protein in HIV infection of nondividing cells. PLoS Pathog. 2007, 3, 1502–1510. 
92.  Dismuke,  D.J.;  Aiken,  C.  Evidence  for  a  functional  link  between  uncoating  of  the  human 
immunodeficiency  virus  type  1  core  and  nuclear  import  of  the  viral  preintegration  complex.  
J. Virol. 2006, 80, 3712–3720. 
93.  Qi, M.; Yang, R.; Aiken, C. Cyclophilin A-dependent restriction of human immunodeficiency 
virus type 1 capsid mutants for infection of nondividing cells. J. Virol. 2008, 82, 12001–12008. 
94.  Lee, K.; Ambrose, Z.; Martin, T.D.; Oztop, I.; Mulky, A.; Julias, J.G.; Vandegraaff, N.; Baumann, 
J.G.; Wang, R.; Yuen, W.; et al. Flexible use of nuclear import pathways by HIV-1. Cell Host 
Microbe 2010, 7, 221–233. 
95.  Arfi,  V.;  Lienard,  J.;  Nguyen,  X.N.;  Berger,  G.;  Rigal,  D.;  Darlix,  J.L.;  Cimarelli,  A. 
Characterization of the behavior of functional viral genomes during the early steps of human 
immunodeficiency virus type 1 infection. J. Virol. 2009, 83, 7524–7535. 
96.  Wacharapornin,  P.;  Lauhakirti,  D.;  Auewarakul,  P.  The  effect  of  capsid  mutations  on  HIV-1 
uncoating. Virology 2007, 358, 48–54. 
97.  Arhel, N.J.; Souquere-Besse, S.; Munier, S.; Souque, P.; Guadagnini, S.; Rutherford, S.; Prevost, 
M.C.;  Allen,  T.D.;  Charneau,  P.  HIV-1  DNA  Flap  formation  promotes  uncoating  of  the  
pre-integration complex at the nuclear pore. EMBO J. 2007, 26, 3025–37. Viruses 2011, 3                                       
 
 
152 
98.  Iordanskiy, S.; Berro, R.; Altieri, M.; Kashanchi, F.; Bukrinsky, M. Intracytoplasmic maturation 
of the human immunodeficiency virus type 1 reverse transcription complexes determines their 
capacity to integrate into chromatin. Retrovirology 2006, 3, 4. 
99.  Brass, A.L.; Dykxhoorn, D.M.; Benita, Y.; Yan, N.; Engelman, A.; Xavier, R.J.; Lieberman, J.; 
Elledge,  S.J.  Identification  of  host  proteins  required  for  HIV  infection  through  a  functional 
genomic screen. Science 2008, 319, 921–926. 
100. Konig, R.; Zhou, Y.; Elleder, D.; Diamond, T.L.; Bonamy, G.M.; Irelan, J.T.; Chiang, C.Y.; Tu, 
B.P.; De Jesus, P.D.; Lilley, C.E.; et al. Global analysis of host-pathogen interactions that regulate 
early-stage HIV-1 replication. Cell 2008, 135, 49–60. 
101. Zhou,  H.;  Xu,  M.;  Huang,  Q.;  Gates,  A.T.;  Zhang,  X.D.;  Castle,  J.C.;  Stec,  E.;  Ferrer,  M.; 
Strulovici, B.; Hazuda, D J.; Espeseth, A.S. Genome-scale RNAi screen for host factors required 
for HIV replication. Cell Host Microbe 2008, 4, 495–504. 
102. Ao, Z.; Danappa Jayappa, K.; Wang, B.; Zheng, Y.; Kung, S.; Rassart, E.; Depping, R.; Kohler, 
M.; Cohen, E. A.; Yao, X. Importin alpha3 interacts with HIV-1 integrase and contributes to  
HIV-1 nuclear import and replication. J. Virol. 2010, 84, 8650–8663. 
103. Fassati,  A.;  Gorlich,  D.;  Harrison,  I.;  Zaytseva,  L.;  Mingot,  J.M.  Nuclear  import  of  HIV-1 
intracellular  reverse  transcription  complexes  is  mediated  by  importin  7.  EMBO  J.  2003,  22,  
3675–3685. 
104. Christ, F.; Thys, W.; De Rijck, J.; Gijsbers, R.; Albanese, A.; Arosio, D.; Emiliani, S.; Rain, J.C.; 
Benarous, R.; Cereseto, A.; Debyser, Z. Transportin-SR2 imports HIV into the nucleus. Curr. 
Biol. 2008, 18, 1192–1202. 
105. Ao, Z.; Huang, G.; Yao, H.; Xu, Z.; Labine, M.; Cochrane, A. W.; Yao, X. Interaction of human 
immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its 
impact on viral replication. J. Biol. Chem. 2007, 282, 13456–13467. 
106. Krishnan, L.; Matreyek, K.A.; Oztop, I.; Lee, K.; Tipper, C.H.; Li, X.; Dar, M.J.; Kewalramani, 
V.N.; Engelman, A. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during 
infection maps to human immunodeficiency virus type 1 capsid and not integrase. J. Virol. 2010, 
84, 397–406. 
107. Mann, R.; Mulligan, R.C.; Baltimore, D. Construction of a retrovirus packaging mutant and its 
use to produce helper-free defective retrovirus. Cell 1983, 33, 153–159. 
108. Helseth,  E.;  Kowalski,  M.;  Gabuzda,  D.;  Olshevsky,  U.;  Haseltine,  W.;  Sodroski,  J.  Rapid 
complementation assays measuring replicative potential of human immunodeficiency virus type 1 
envelope glycoprotein mutants. J. Virol. 1990, 64, 2416–2420. 
109. Page, K.A.; Landau, N.R.; Littman, D.R. Construction and use of a human immunodeficiency 
virus vector for analysis of virus infectivity. J. Virol. 1990, 64, 5270–5276. 
110. Landau, N.R.; Page, K.A.; Littman, D.R. Pseudotyping with human T-cell leukemia virus type I 
broadens the human immunodeficiency virus host range. J. Virol. 1991, 65, 162–169. 
111. Poznansky, M.; Lever, A.; Bergeron, L.; Haseltine, W.; Sodroski, J. Gene transfer into human 
lymphocytes by a defective human immunodeficiency virus type 1 vector. J. Virol. 1991, 65,  
532–536. 
112. Buchschacher, G.L. Jr.; Panganiban, A.T. Human immunodeficiency virus vectors for inducible 
expression of foreign genes. J. Virol. 1992, 66, 2731–2739. Viruses 2011, 3                                       
 
 
153 
113. Parolin, C.; Dorfman, T.; Palu, G.; Gottlinger, H.; Sodroski, J. Analysis in human immunodeficiency 
virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes.  
J. Virol. 1994, 68, 3888–3895. 
114. Zufferey, R.; Nagy, D.; Mandel, R.J.; Naldini, L.; Trono, D. Multiply attenuated lentiviral vector 
achieves efficient gene delivery in vivo. Nat. Biotechnol. 1997, 15, 871–875. 
115. Dull, T.; Zufferey, R.; Kelly, M.; Mandel, R.J.; Nguyen, M.; Trono, D.; Naldini, L. A third-
generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72, 8463–8471. 
116. Zufferey, R.; Donello, J.E.; Trono, D.; Hope, T.J. Woodchuck hepatitis virus posttranscriptional 
regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 
1999, 73, 2886–2892. 
117. Sun, J.; Li, D.; Hao, Y.; Zhang, Y.; Fan, W.; Fu, J.; Hu, Y.; Liu, Y.; Shao, Y. Posttranscriptional 
regulatory elements enhance antigen expression and DNA vaccine efficacy. DNA Cell Biol. 2009, 
28, 233–240. 
118. Iwakuma,  T.;  Cui,  Y.;  Chang,  L.J.  Self-inactivating  lentiviral  vectors  with  U3  and  U5 
modifications. Virology 1999, 261, 120–132. 
119. Schambach, A.; Bohne, J.;  Chandra, S.;  Will, E.;  Margison, G.P.; Williams,  D.A.; Baum,  C. 
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-
DNA methyltransferase in hematopoietic cells. Mol. Ther. 2006, 13, 391–400. 
120. Miyoshi,  H.;  Blomer,  U.;  Takahashi,  M.;  Gage,  F.H.;  Verma,  I.M.  Development  of  a  self-
inactivating lentivirus vector. J. Virol. 1998, 72, 8150–8157. 
121. Zufferey, R.; Dull, T.; Mandel, R.J.; Bukovsky, A.; Quiroz, D.; Naldini, L.; Trono, D. Self-inactivating 
lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72, 9873–9880. 
122. Bokhoven, M.; Stephen, S.L.; Knight, S.; Gevers, E.F.; Robinson, I.C.; Takeuchi, Y.; Collins, 
M.K. Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 2009, 83, 
283–294. 
123. Zennou, V.; Serguera, C.; Sarkis, C.; Colin, P.; Perret, E.; Mallet, J.; Charneau, P. The HIV-1 
DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat. Biotechnol. 2001, 
19, 446–450. 
124. Sandrin,  V.;  Russell,  S.J.;  Cosset,  F.L.  Targeting  retroviral  and  lentiviral  vectors.  Curr.  Top. 
Microbiol. Immunol. 2003, 281, 137–178. 
125. Geijtenbeek, T.B.; Torensma, R.; van Vliet, S.J.; van Duijnhoven, G.C.; Adema, G.J.; van Kooyk, 
Y.; Figdor, C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that 
supports primary immune responses. Cell 2000, 100, 575–585. 
126. Yang, L.; Yang, H.; Rideout, K.; Cho, T.; Joo, K.I.; Ziegler, L.; Elliot, A.; Walls, A.; Yu, D.; 
Baltimore,  D.;  Wang,  P.  Engineered  lentivector  targeting  of  dendritic  cells  for  in  vivo 
immunization. Nat. Biotechnol. 2008, 26, 326–334. 
127. Yang, L.; Bailey, L.; Baltimore, D.; Wang, P. Targeting lentiviral vectors to specific cell types in 
vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 11479–11484. 
128. Serafini,  M.;  Naldini,  L.;  Introna,  M.  Molecular  evidence  of  inefficient  transduction  of 
proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. Virology 
2004, 325, 413–424. Viruses 2011, 3                                       
 
 
154 
129. Frecha, C.; Costa, C.; Levy, C.; Negre, D.; Russell, S.J.; Maisner, A.; Salles, G.; Peng, K.W.; 
Cosset,  F.L.;  Verhoeyen,  E.  Efficient  and  stable  transduction  of  resting  B  lymphocytes  and 
primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. 
Blood 2009, 114, 3173–3180. 
130. Verhoeyen, E.; Dardalhon, V.; Ducrey-Rundquist, O.; Trono, D.; Taylor, N.; Cosset, F.L. IL-7 
surface-engineered  lentiviral  vectors  promote  survival  and  efficient  gene  transfer  in  resting 
primary T lymphocytes. Blood 2003, 101, 2167–2174. 
131. Azzouz, M.; Ralph, G.S.; Storkebaum, E.; Walmsley, L.E.; Mitrophanous, K.A.; Kingsman, S.M.; 
Carmeliet, P.; Mazarakis, N.D. VEGF delivery with retrogradely transported lentivector prolongs 
survival in a mouse ALS model. Nature 2004, 429, 413–417. 
132. Mazarakis, N.D.; Azzouz, M.; Rohll, J.B.; Ellard, F.M.; Wilkes, F.J.; Olsen, A.L.; Carter, E.E.; 
Barber, R.D.; Baban, D.F.; Kingsman, S.M.; Kingsman, A.J.; O’Malley, K.; Mitrophanous, K.A. 
Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and 
access to the nervous system after peripheral delivery. Hum. Mol. Genet. 2001, 10, 2109–2121. 
133. Goujon, C.; Jarrosson-Wuilleme, L.; Bernaud, J.; Rigal, D.; Darlix, J.L.; Cimarelli, A. With a 
little help from a friend: Increasing HIV transduction of monocyte-derived dendritic cells with 
virion-like particles of SIV(MAC). Gene Ther. 2006, 13, 991–994. 
134. Goujon, C.; Riviere, L.; Jarrosson-Wuilleme, L.; Bernaud, J.; Rigal, D.; Darlix, J.L.; Cimarelli, A. 
SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction 
pathway present in human dendritic cells. Retrovirology 2007, 4, 2. 
135. Goujon,  C.;  Arfi,  V.;  Pertel,  T.;  Luban,  J.;  Lienard,  J.;  Rigal,  D.;  Darlix,  J.L.;  Cimarelli,  A. 
Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 
2 Vpx function in human myeloid cells. J. Virol. 2008, 82, 12335–12345. 
136. Bergamaschi, A.; Ayinde, D.; David, A.; Le Rouzic, E.; Morel, M.; Collin, G.; Descamps, D.; 
Damond, F.; Brun-Vezinet, F.; Nisole, S.; Margottin-Goguet, F.; Pancino, G.; Transy, C. The 
human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin 
ligase to overcome a postentry block in macrophage infection. J. Virol. 2009, 83, 4854–4860. 
137. Srivastava, S.; Swanson, S.K.; Manel, N.; Florens, L.; Washburn, M.P.; Skowronski, J. Lentiviral 
Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to 
enable macrophage infection. PLoS Pathog. 2008, 4, e1000059. 
138. Sharova, N.; Wu, Y.; Zhu, X.; Stranska, R.; Kaushik, R.; Sharkey, M.; Stevenson, M. Primate 
lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog. 2008, 4, 
e1000057. 
139. Hirsch, V.M.; Sharkey, M.E.; Brown, C.R.; Brichacek, B.; Goldstein, S.; Wakefield, J.; Byrum, 
R.; Elkins, W.R.; Hahn, B.H.; Lifson, J.D.; Stevenson, M. Vpx is required for dissemination and 
pathogenesis of SIV(SM) PBj: Evidence of macrophage-dependent viral amplification. Nat. Med. 
1998, 4, 1401–1408. 
140. Berger, G.; Goujon, C.; Darlix, J.L.; Cimarelli, A. SIVMAC Vpx improves the transduction of 
dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther. 2009, 16, 159–163. 
141. Chen, X.; He, J.; Chang, L.J. Alteration of T cell immunity by lentiviral transduction of human 
monocyte-derived dendritic cells. Retrovirology 2004, 1, 37. Viruses 2011, 3                                       
 
 
155 
142. Tan, P.H.; Beutelspacher, S.C.; Xue, S.A.; Wang, Y.H.; Mitchell, P.; McAlister, J.C.; Larkin, 
D.F.;  McClure,  M.O.;  Stauss,  H.J.;  Ritter,  M.A.;  Lombardi,  G.;  George,  A.J.  Modulation  of 
human dendritic-cell function following transduction with viral vectors: Implications for gene 
therapy. Blood 2005, 105, 3824–3832. 
143. Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits 
HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418, 646–650. 
144. Stremlau,  M.;  Owens,  C.M.;  Perron,  M.J.;  Kiessling,  M.;  Autissier,  P.;  Sodroski,  J.  The 
cytoplasmic  body  component  TRIM5alpha  restricts  HIV-1  infection  in  Old  World  monkeys. 
Nature 2004, 427, 848–853. 
145. LaBonte, J.A.; Babcock, G.J.; Patel, T.; Sodroski, J. Blockade of HIV-1 infection of New World 
monkey cells occurs primarily at the stage of virus entry. J. Exp. Med. 2002, 196, 431–445. 
146. Cowan, S.; Hatziioannou, T.; Cunningham, T.; Muesing, M.A.; Gottlinger, H.G.; Bieniasz, P.D. 
Cellular  inhibitors  with  Fv1-like  activity  restrict  human  and  simian  immunodeficiency  virus 
tropism. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 11914–11919. 
147. Hatziioannou, T.; Cowan, S.; Goff, S.P.; Bieniasz, P.D.; Towers, G.J. Restriction of multiple 
divergent retroviruses by Lv1 and Ref1. EMBO J. 2003, 22, 385–394. 
148. Stremlau, M.; Perron, M.; Lee, M.; Li, Y.; Song, B.; Javanbakht, H.; Diaz-Griffero, F.; Anderson, 
D.J.;  Sundquist,  W.I.;  Sodroski,  J.  Specific  recognition  and  accelerated  uncoating  of  retroviral 
capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 5514–5519. 
149. Anderson, J.L.; Campbell, E.M.; Wu, X.; Vandegraaff, N.; Engelman, A.; Hope, T.J. Proteasome 
inhibition reveals that a functional preintegration complex intermediate can be generated during 
restriction by diverse TRIM5 proteins. J. Virol. 2006, 80, 9754–9760. 
150. Campbell, E.M.; Dodding, M.P.; Yap, M.W.; Wu, X.; Gallois-Montbrun, S.; Malim, M.H.; Stoye, 
J.P.; Hope, T.J. TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol. Biol. Cell. 
2007, 18, 2102–2111. 
151. Towers,  G.J.  The  control  of  viral  infection  by  tripartite  motif  proteins  and  cyclophilin  A. 
Retrovirology 2007, 4, 40. 
152. Ikeda, Y.; Collins, M.K.; Radcliffe, P.A.; Mitrophanous, K.A.; Takeuchi, Y. Gene transduction 
efficiency in cells of different species by HIV and EIAV vectors. Gene Ther. 2002, 9, 932–938. 
153. Saenz, D.T.; Teo, W.; Olsen, J.C.; Poeschla, E.M. Restriction of feline immunodeficiency virus 
by Ref1, Lv1, and primate TRIM5alpha proteins. J. Virol. 2005, 79, 15175–15188. 
154. Schaller,  T.;  Hue,  S.;  Towers,  G.J.  An  active  TRIM5  protein  in  rabbits  indicates  a  common 
antiviral ancestor for mammalian TRIM5 proteins. J. Virol. 2007, 81, 11713–11721. 
155. Ylinen, L.M.; Keckesova, Z.; Webb, B.L.; Gifford, R.J.; Smith, T.P.; Towers, G.J. Isolation of an 
active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to 
retroviral infection is widespread among mammals. J. Virol. 2006, 80, 7332–7338. 
156. Si, Z.; Vandegraaff, N.; O’Huigin, C.; Song, B.; Yuan, W.; Xu, C.; Perron, M.; Li, X.; Marasco, 
W.A.; Engelman, A.; Dean, M.; Sodroski, J.  Evolution of a cytoplasmic tripartite motif (TRIM) 
protein in cows that restricts retroviral infection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7454–7459. 
157. Tervo, H.M.; Keppler, O.T. High Natural Permissivity of Primary Rabbit Cells for HIV-1 with a 
Virion Infectivity Defect in Macrophages as the Final Replication Barrier. J. Virol. 2010, 84, 
12300–12314. Viruses 2011, 3                                       
 
 
156 
158. Mukherjee, S.; Lee, H.L.; Pacchia, A.L.; Ron, Y.; Dougherty, J.P. A HIV-2-based self-inactivating 
vector for enhanced gene transduction. J. Biotechnol. 2007, 127, 745–757. 
159. Morris, K.V.; Looney, D.J. Characterization of human immunodeficiency virus (HIV)-2 vector 
mobilization by HIV-1. Hum. Gene Ther. 2005, 16, 1463–1472. 
160. Griffin, S.D.; Allen, J.F.; Lever, A.M. The major human immunodeficiency virus type 2 (HIV-2) 
packaging signal is present on all HIV-2 RNA species: Cotranslational RNA encapsidation and 
limitation of Gag protein confer specificity. J. Virol. 2001, 75, 12058–12069. 
161. D’Costa, J.; Brown, H.; Kundra, P.; Davis-Warren, A.; Arya, S. Human immunodeficiency virus 
type  2  lentiviral  vectors:  Packaging  signal  and  splice  donor  in  expression  and  encapsidation.  
J. Gen. Virol. 2001, 82, 425–434. 
162. Arya, S.K.; Zamani, M.; Kundra, P. Human immunodeficiency virus type 2 lentivirus vectors for 
gene transfer: Expression and potential for helper virus-free packaging. Hum Gene Ther 1998, 9, 
1371–1380. 
163. Poeschla,  E.;  Corbeau,  P.;  Wong-Staal,  F.  Development  of  HIV  vectors  for  anti-HIV  gene 
therapy. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 11395–11399. 
164. Garzino-Demo,  A.;  Gallo,  R.C.;  Arya,  S.K.  Human  immunodeficiency  virus  type  2  (HIV-2): 
Packaging signal and associated negative regulatory element. Hum. Gene Ther. 1995, 6, 177–184. 
165. Kaye, J.F.; Lever, A.M. Nonreciprocal packaging of human immunodeficiency virus type 1 and 
type 2 RNA: A possible role for the p2 domain of Gag in RNA encapsidation. J. Virol. 1998, 72, 
5877–5885. 
166. Pandya,  S.;  Boris-Lawrie,  K.;  Leung,  N.J.;  Akkina,  R.;  Planelles,  V.  Development  of  an  
Rev-independent,  minimal  simian  immunodeficiency  virus-derived  vector  system.  Hum.  Gene 
Ther. 2001, 12, 847–857. 
167. Schnell,  T.;  Foley,  P.;  Wirth,  M.;  Munch,  J.;  Uberla,  K.  Development  of  a  self-inactivating, 
minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 2000, 11, 
439–447. 
168. Mangeot, P.E.; Negre, D.; Dubois, B.; Winter, A.J.; Leissner, P.; Mehtali, M.; Kaiserlian, D.; 
Cosset,  F.L.;  Darlix,  J.L.  Development  of  minimal  lentivirus  vectors  derived  from  simian 
immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. 
J. Virol. 2000, 74, 8307–8315. 
169. Stitz, J.; Muhlebach, M. D.; Blomer, U.; Scherr, M.; Selbert, M.; Wehner, P.; Steidl, S.; Schmitt, 
I.; Konig, R.; Schweizer, M.; Cichutek, K. A novel lentivirus vector derived from apathogenic 
simian immunodeficiency virus. Virology 2001, 291, 191–197. 
170. O'Rourke,  J.P.;  Olsen,  J.C.;  Bunnell,  B.A.  Optimization  of  equine  infectious  anemia  derived 
vectors for hematopoietic cell lineage gene transfer. Gene Ther. 2005, 12, 22–29. 
171. Olsen, J.C. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 1998, 
5, 1481–1487. 
172. Mitrophanous, K.; Yoon, S.; Rohll, J.; Patil, D.; Wilkes, F.; Kim, V.; Kingsman, S.; Kingsman, 
A.; Mazarakis, N. Stable gene transfer to the nervous system using a non-primate lentiviral vector. 
Gene Ther. 1999, 6, 1808–1818. 
173. Poeschla, E.M.; Wong-Staal, F.; Looney, D.J. Efficient transduction of nondividing human cells 
by feline immunodeficiency virus lentiviral vectors. Nat. Med. 1998, 4, 354–357. Viruses 2011, 3                                       
 
 
157 
174. Johnston, J.C.; Gasmi, M.; Lim, L.E.; Elder, J.H.; Yee, J.K.; Jolly, D.; Campbell, K.P.; Davidson, 
B.L.; Sauter, S.L. Minimum requirements for efficient transduction of dividing and nondividing 
cells by feline immunodeficiency virus vectors. J. Virol. 1999, 73, 4991–5000. 
175. Khare, P.D.; Loewen, N.; Teo, W.; Barraza, R.A.; Saenz, D.T.; Johnson, D.H.; Poeschla, E.M. 
Durable, safe, multi-gene lentiviral vector expression in feline trabecular meshwork. Mol. Ther. 
2008, 16, 97–106. 
176. Berkowitz, R.D.; Ilves, H.; Plavec, I.; Veres, G. Gene transfer systems derived from Visna virus: 
Analysis of virus production and infectivity. Virology 2001, 279, 116–129. 
177. Mselli-Lakhal,  L.;  Favier,  C.;  Da  Silva  Teixeira,  M.F.;  Chettab,  K.;  Legras,  C.;  Ronfort,  C.; 
Verdier,  G.;  Mornex,  J.F.;  Chebloune,  Y.  Defective  RNA  packaging  is  responsible  for  low 
transduction efficiency of CAEV-based vectors. Arch. Virol. 1998, 143, 681–695. 
178. Mselli-Lakhal, L.; Guiguen, F.; Greenland, T.; Mornex, J.F.; Chebloune, Y. Gene transfer system 
derived from the caprine arthritis-encephalitis lentivirus. J. Virol. Methods 2006, 136, 177–184. 
179. Metharom, P.; Takyar, S.; Xia, H. H.; Ellem, K.A.; Macmillan, J.; Shepherd, R.W.; Wilcox, G.E.; 
Wei, M.Q. Novel bovine lentiviral vectors based on Jembrana disease virus. J. Gene Med. 2000, 
2, 176–85. 
180. Berkowitz, R.; Ilves, H.; Lin, W. Y.; Eckert, K.; Coward, A.; Tamaki, S.; Veres, G.; Plavec, I. 
Construction  and  molecular  analysis  of  gene  transfer  systems  derived  from  bovine 
immunodeficiency virus. J. Virol. 2001, 75, 3371–82. 
181. Matukonis, M.; Li, M.; Molina, R.P.; Paszkiet, B.; Kaleko, M.; Luo, T. Development of second- 
and  third-generation bovine immunodeficiency virus-based gene  transfer  systems.  Hum.  Gene 
Ther. 2002, 13, 1293–1303. 
182. Brandt, S.; Blissenbach, M.; Grewe, B.; Konietzny, R.; Grunwald, T.; Uberla, K. Rev proteins of 
human and simian immunodeficiency virus enhance RNA encapsidation. PLoS Pathog. 2007, 3, e54. 
183. Bordignon, C.; Yu, S.F.; Smith, C.A.; Hantzopoulos, P.; Ungers, G.E.; Keever, C.A.; O’Reilly, 
R.J.; Gilboa, E. Retroviral vector-mediated high-efficiency expression of adenosine deaminase 
(ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells. Proc. Natl. Acad. Sci. 
U. S. A. 1989, 86, 6748–6752. 
184. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, 
P.;  Lim,  A.;  Osborne,  C.S.;  Pawliuk,  R.;  Morillon,  E.;  et  al.  LMO2-associated  clonal  T  cell 
proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415–419. 
185. Mitchell,  R.S.;  Beitzel,  B.F.;  Schroder,  A.R.;  Shinn,  P.;  Chen,  H.;  Berry,  C.C.;  Ecker,  J.R.; 
Bushman,  F.D.  Retroviral  DNA  integration:  ASLV,  HIV,  and  MLV  show  distinct  target  site 
preferences. PLoS Biol. 2004, 2, E234. 
186. Wang, G.P.; Ciuffi, A.; Leipzig, J.; Berry, C.C.; Bushman, F.D. HIV integration site selection: 
Analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. 
Genome Res. 2007, 17, 1186–1194. 
187. Ciuffi, A.; Llano, M.; Poeschla, E.; Hoffmann, C.; Leipzig, J.; Shinn, P.; Ecker, J.R.; Bushman, F. 
A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 2005, 11, 1287–1289. 
188. Busschots, K.; Vercammen, J.; Emiliani, S.; Benarous, R.; Engelborghs, Y.; Christ, F.; Debyser, 
Z.  The  interaction  of  LEDGF/p75  with  integrase  is  lentivirus-specific  and  promotes  DNA 
binding. J. Biol. Chem. 2005, 280, 17841–17847. Viruses 2011, 3                                       
 
 
158 
189. Llano,  M.;  Saenz,  D.T.;  Meehan,  A.;  Wongthida,  P.;  Peretz,  M.;  Walker,  W.H.;  Teo,  W.; 
Poeschla, E.M. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314, 461–464. 
190. Ferris, A.L.; Wu, X.; Hughes, C.M.; Stewart, C.; Smith, S.J.; Milne, T.A.; Wang, G.G.; Shun, 
M.C.; Allis, C.D.; Engelman, A.; Hughes, S.H. Lens epithelium-derived growth factor fusion 
proteins redirect HIV-1 DNA integration. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 3135–3140. 
191. Ciuffi, A.; Diamond, T.L.; Hwang, Y.; Marshall, H.M.; Bushman, F.D. Modulating target site 
selection during human immunodeficiency virus DNA integration  in vitro with an engineered 
tethering factor. Hum. Gene Ther. 2006, 17, 960–967. 
192. Gijsbers,  R.;  Ronen,  K.;  Vets,  S.;  Malani,  N.;  De  Rijck,  J.;  McNeely,  M.;  Bushman,  F.D.; 
Debyser, Z. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. 
Ther. 2010, 18, 552–560. 
193. Huser, D.; Gogol-Doring, A.; Lutter, T.; Weger, S.; Winter, K.; Hammer, E. M.; Cathomen, T.; 
Reinert, K.; Heilbronn, R. Integration preferences of wildtype AAV-2 for consensus rep-binding 
sites at numerous loci in the human genome. PLoS Pathog. 2010, 6, e1000985. 
194. Huser,  D.;  Weger,  S.;  Heilbronn,  R.  Packaging  of  human  chromosome  19-specific  adeno-
associated virus (AAV) integration sites in AAV virions during AAV wild-type and recombinant 
AAV vector production. J. Virol. 2003, 77, 4881–4887. 
195. Grizot,  S.;  Epinat,  J.C.;  Thomas,  S.;  Duclert,  A.;  Rolland,  S.;  Paques,  F.;  Duchateau,  P. 
Generation of redesigned homing endonucleases comprising DNA-binding domains derived from 
two different scaffolds. Nucleic Acids Res. 2010, 38, 2006–2018. 
196. Thierry, A.; Dujon, B. Nested chromosomal fragmentation in yeast using the meganuclease I-Sce 
I: A new method for physical mapping of eukaryotic genomes.  Nucleic Acids Res. 1992, 20, 
5625–5631. 
197. Saenz, D.T.; Loewen, N.; Peretz, M.; Whitwam, T.; Barraza, R.; Howell, K.G.; Holmes, J.M.; 
Good, M.; Poeschla, E.M. Unintegrated lentivirus DNA persistence and accessibility to expression 
in nondividing cells: Analysis with class I integrase mutants. J. Virol. 2004, 78, 2906–2920. 
198. Nakajima, N.; Lu, R.; Engelman, A. Human immunodeficiency virus type 1 replication in the 
absence of integrase-mediated dna recombination: Definition of permissive and nonpermissive  
T-cell lines. J. Virol. 2001, 75, 7944–7955. 
199. Cara, A.; Guarnaccia, F.; Reitz, M.S.; Gallo, R.C.; Lori, F. Self-limiting, cell type-dependent 
replication of an integrase-defective human immunodeficiency virus type 1 in human primary 
macrophages but not T lymphocytes. Virology 1995, 208, 242–248. 
200. Negri, D.R.; Bona, R.; Michelini, Z.; Leone, P.; Macchia, I.; Klotman, M.E.; Salvatore, M.; Cara, 
A.  Transduction  of  human  antigen-presenting  cells  with  integrase-defective  lentiviral  vector 
enables functional expansion of primed antigen-specific CD8(+) T cells. Hum. Gene Ther. 2010, 
21, 1029–1035. 
201. Wiskerchen, M.; Muesing, M.A. Human immunodeficiency virus type 1 integrase:  Effects of 
mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA 
templates, and sustain viral propagation in primary cells. J. Virol. 1995, 69, 376–386. 
202. Engelman,  A.;  Englund,  G.;  Orenstein,  J.M.;  Martin,  M.A.;  Craigie,  R.  Multiple  effects  of 
mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 1995, 
69, 2729–2736. Viruses 2011, 3                                       
 
 
159 
203. Wu,  Y.;  Marsh,  J.W.  Selective  transcription  and  modulation  of  resting  T  cell  activity  by 
preintegrated HIV DNA. Science 2001, 293, 1503–1506. 
©  2011  by  the authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 